Ayhan BİLİR, Gamze TANRIVERDİ, Şule AYLA, Şenol ERTÜRKOĞLU, Kenan SOFUOĞLU, B. Cem SONER, Laura GHISOLFI, Gülperi ÖKTEM

Effects of different drug treatments on the proliferation of human ovarian carcinoma cell line MDAH-2774

Background/aim: In this study, the effects of resveratrol as a natural polyphenol compound, gemcitabine as an antimetabolite thathas nucleoside structure analogous to deoxycytidine, and para-aminophenol-derived paracetamol were investigated with single andcombined applications in monolayers of the MDAH-2774 human ovarian cancer cell line.Materials and methods: Drugs were evaluated in cell culture with respect to cell proliferation, cell cytotoxicity (trypan blue dyeexclusion test), synthesis phase of cell cycle, and cell structure in 24, 48, 72, and 96 h.Result: Resveratrol and gemcitabine diminished both cell proliferation and cell cycle synthesis phase indication in monolayer cellcultures (P < 0.05). All combination groups showed similar effects that were mainly more effective in respect to single usage of resveratroland gemcitabine in monolayer cell cultures.Conclusion: The effects of gemcitabine, resveratrol, and paracetamol were investigated in monolayers of the MDAH-2774 humanovarian cancer cell line and a decrease in cell number in cell cycle synthesis phase, prevention of cell proliferation, and destruction ofcell structure were observed.

PDF

___

Marczak A, Denel M. Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells. Contemp Oncol (Pozn) 2014; 18: 149-152.
Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
Di J, Duiveman-de Boer T, Figdor CG, Torensma R. Aiming to immune elimination of ovarian cancer stem cells. World J Stem Cells 2013; 5: 149-162.
Kaufmann M, von Minckwitz G. Gemcitabine in ovarian cancer: an overview of safety and efficacy. Eur J Cancer 1997; 33: 31-33.
Chanpanitkitchot S, Tangjitgamol S, Khunnarong J, Thavaramara T, Pataradool K, Srijaipracharoen S. Treatment outcomes of gemcitabine in refractory or recurrent epithelial ovarian cancer patients. Asian Pac J Cancer Prev 2014; 15: 5215-5221.
Kristensen DM, Mazaud-Guittot S, Gaudriault P, Lesne L, Serrano T, Main KM, Jegou B. Analgesic use – prevalence, biomonitoring and endocrine and reproductive effects. Nat Rev Endocrinol 2016; 12: 381-393.
Jégou B. Paracetamol-induced endocrine disruption in human fetal testes. Nat Rev Endocrinol 2015; 11: 453-454.
Ozdemirler G, Aykac G, Uysal M, Oz H. Liver lipid peroxidation and glutathione-related defence enzyme systems in mice treated with paracetamol. J Appl Toxicol 1994; 14: 297-299.
Bilir A, Altinoz MA, Attar E, Erkan M, Aydiner A. Acetaminophen modulations of chemotherapy efficacy in MDAH 2774 human endometrioid ovarian cancer cells in vitro. Neoplasma 2002; 49: 38-42.
Smith HS, Wolman SR, Hackett AJ. The biology of breast cancer at the cellular level. Biochim Biophys Acta 1984; 738: 103-123.
Eo SH, Cho H, Kim SJ. Resveratrol inhibits nitric oxideinduced apoptosis via the NF-kappa B pathway in rabbit articular chondrocytes. Biomol Ther (Seoul) 2013; 21: 364-370.
Wenzel E, Somoza V. Metabolism and bioavailability of transresveratrol. Mol Nutr Food Res 2005; 49: 472-481.
Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397-1421.
Engel N, Falodun A, Kühn J, Kragl U, Langer P, Nebe B. Pro-apoptotic and anti-adhesive effects of four African plant extracts on the breast cancer cell line MCF-7. BMC Complement Altern Med 2014 ; 14: 334.
Cakir Z, Saydam G, Sahin F, Baran Y. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J Cancer Res Clin Oncol 2011; 137: 279-286.
Aluyen JK, Ton QN, Tran T, Yang AE, Gottlieb HB, Bellanger RA. Resveratrol: potential as anticancer agent. J Diet Suppl 2012; 9: 45-56.
Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon EA. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 2007; 28: 282-293.
Riles WL, Erickson J, Nayyar S, Atten MJ, Attar BM, Holian O. Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J Gastroenterol 2006; 12: 5628- 5634.
Luque I, Gelinas C. Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin Cancer Biol 1997; 8: 103-111.
Sharma HW, Narayanan R. The NF-kappaB transcription factor in oncogenesis. Anticancer Res 1996; 16: 589-596.
Pervaiz S. Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol. Drug Resist Updat 2004; 7: 333-344.
Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000; 164: 6509-6519.
Yip-Schneider MT, Sweeney CJ, Jung SH, Crowell PL, Marshall MS. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001; 298: 976-985.
Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992; 10: 406-413.
Meric A, Bilir A. Inflammation, Nonsteroid and steroid antiinflammatory agents and ovarian cancer. In: Bardos AP, editor. Treatment of Ovarian Cancer. New York, NY, USA: Nova Biomedical Books; 2004. pp. 101-137.
Bilir A, Guneri AD, Altinoz MA. Acetaminophen and DMSO modulate growth and gemcitabine cytotoxicity in FM3A breast cancer cells in vitro. Neoplasma 2004; 51: 460-464.
Draper MP, Martell RL, Levy SB. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer 1997; 75: 810-815.